EPA and DHA supplementation ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
48	Primary antiphospholipid syndrome	1
49	Systemic lupus erythematosus	1

48. Primary antiphospholipid syndrome

---

Clinical trials : 4 /  Drugs : 5 - (DrugBank : 3) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01956188 (ClinicalTrials.gov)	May 2014	25/9/2013	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	NULL	Active, not recruiting	20 Years	45 Years	Female	22	N/A	Brazil

49. Systemic lupus erythematosus

---

Clinical trials : 946 /  Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01956188 (ClinicalTrials.gov)	May 2014	25/9/2013	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	NULL	Active, not recruiting	20 Years	45 Years	Female	22	N/A	Brazil